In-office Gene Therapy Adverum is pursuing durable, single-administration IVT gene therapy designed for in-office delivery to physicians, presenting a sales opportunity to expand relationships with ophthalmology clinics and reduce patient burden from frequent injections.

One-time Ixo-vec The lead candidate ixoberogene soroparvovec (Ixo-vec) targets wet AMD with a potential one-time treatment, offering a compelling value proposition for payers and providers seeking to lower ongoing treatment costs and improve adherence.

Strategic Acquisition Lilly’s planned acquisition of Adverum signals strong validation and potential for accelerated commercialization, creating collaboration avenues for distribution, manufacturing support, and co-development opportunities.

Clinical Leadership Adverum’s CMC and assay development leadership (e.g., light scattering assays for AAV products) can be leveraged to position the company as a trusted partner for ophthalmic gene therapy programs seeking robust analytics and quality controls.

Financial Backing With substantial funding and a clear clinical-stage trajectory, there is room to pursue partnerships around manufacturing scale, regulatory services, and early access programs to drive near-term revenue generation and de-risk market entry.